Candriam S.C.A. Sells 48,363 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Candriam S.C.A. reduced its stake in Supernus Pharmaceuticals by 44.2%, selling 48,363 shares and retaining a total of 60,964 shares valued at approximately $1.997 million.
• Insider trading activity includes CEO Jack A. Khattar selling 140,000 shares for about $5.88 million, decreasing his ownership by 11.96%.
• Analysts' ratings for Supernus Pharmaceuticals have improved, with Wall Street Zen upgrading the stock to a "buy" and Cantor Fitzgerald raising the price target to $46.00.

Candriam S.C.A. lowered its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 44.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 60,964 shares of the specialty pharmaceutical company's stock after selling 48,363 shares during the period. Candriam S.C.A. owned 0.11% of Supernus Pharmaceuticals worth $1,997,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Raiffeisen Bank International AG acquired a new position in Supernus Pharmaceuticals in the fourth quarter worth approximately $25,000. Financial Management Professionals Inc. acquired a new position in Supernus Pharmaceuticals during the first quarter valued at approximately $30,000. Versant Capital Management Inc grew its holdings in Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after purchasing an additional 1,109 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Supernus Pharmaceuticals during the first quarter valued at approximately $41,000. Finally, GF Fund Management CO. LTD. acquired a new position in Supernus Pharmaceuticals during the fourth quarter valued at approximately $42,000.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Finally, Cantor Fitzgerald lifted their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $41.00.

Insider Transactions at Supernus Pharmaceuticals

In related news, Director Bethany Sensenig sold 5,369 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.25, for a total value of $226,840.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Timothy C. Dec sold 11,780 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $44.49, for a total value of $524,092.20. Following the completion of the sale, the chief financial officer owned 1,246 shares of the company's stock, valued at approximately $55,434.54. The trade was a 90.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 179,606 shares of company stock valued at $7,617,005. 8.80% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Stock Up 1.7%

SUPN stock traded up $0.75 during midday trading on Wednesday, reaching $45.07. The stock had a trading volume of 680,753 shares, compared to its average volume of 641,327. The business has a fifty day simple moving average of $35.88 and a two-hundred day simple moving average of $33.77. The firm has a market cap of $2.53 billion, a price-to-earnings ratio of 39.19 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a twelve month low of $29.16 and a twelve month high of $45.60.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.